Importantly, in CD138+ plasma cells isolated from six t(4;14)-positive patients with disease progression after treatment with bortezomib-based regimens, we found that a remarkable anti-MM effect exceeding the combination range was elicited (Figure 7D). The gene discussed is SDC1; the disease is Miyoshi myopathy.